Parkinson's disease is one of the most common diseases in the elderly population, and the substantia nigra is generally involved in the disease process; however, the signaling pathways and related genes underlying Parkinson's disease remain unclear. This study integrated three cohorts of profile datasets to elucidate the potential key candidate genes and pathways in Parkinson's disease. The expression profiles of GSE8397, GSE20186 and GSE49036 were included 55 available substantia nigra tissue samples from individuals diagnosed with Parkinson's disease and 33 substantia nigra tissue samples from healthy controls. These samples were integrated and thoroughly analyzed. Differentially expressed genes (DEGs) were sorted, and candidate genes and pathway enrichments were analyzed. A DEG-associated protein–protein interaction network analysis was performed. 27 shared downregulated DEGs were identified from the three GSE datasets. The DEGs were clustered based on function and signaling pathway with significant enrichment analysis. 52 edges were identified from the DEG protein–protein interaction network complex, which included dopamine metabolism, nerve conduction, reduced neuronal toxicity and proliferation pathways. Using integrated bioinformatic analysis, we identified candidate genes and pathways in Parkinson's disease that could improve our understanding of underlying molecular events, which could be potential therapeutic targets for Parkinson's disease.
AscherioA. and SchwarzschildM.A., The epidemiology of Parkinson's disease: Risk factors and prevention, Lancet Neurol.15(12) (2016), 1257–1272. doi:10.1016/S1474-4422(16)30230-7.
2.
BaiX., WeyM.C., MartinezP.A., ShiC., FernandezE. and StrongR., Neurochemical and motor changes in mice with combined mutations linked to Parkinson's disease, Pathobiol Aging Age Relat Dis.7(1) (2017), 1267855. doi:10.1080/20010001.2017.1267855.
3.
BatistelaM.S., JosviakN.D., SulzbachC.D. and de SouzaR.L., An overview of circulating cell-free microRNAs as putative biomarkers in Alzheimer's and Parkinson's diseases, Int J Neurosci.127(6) (2017), 547–558. doi:10.1080/00207454.2016.1209754.
4.
BelizaireR., KomanduriC., WootenK., ChenM., ThallerC. and JanzR., Characterization of synaptogyrin 3 as a new synaptic vesicle protein, J Comp Neurol.470(3) (2004), 266–281. doi:10.1002/cne.20008.
d'Anglemont de TassignyX., PascualA. and Lopez-BarneoJ., GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease, Front Neuroanat.9 (2015), 10.
7.
DettmerU., NewmanA.J., SoldnerF., LuthE.S., von KimN.C., SauckenV.E.et al., Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation, Nat Commun.6 (2015), 7314. doi:10.1038/ncomms8314.
8.
DijkstraA.A., IngrassiaA., de MenezesR.X., van KesterenR.E., RozemullerA.J., HeutinkP.et al., Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson's disease, PLoS One.10(6) (2015), e0128651.
9.
DomanskyiA., SaarmaM. and AiravaaraM., Prospects of neurotrophic factors for Parkinson's disease: Comparison of protein and gene therapy, Hum Gene Ther.26(8) (2015), 550–559. doi:10.1089/hum.2015.065.
10.
DrinkutA., TillackK., MekaD.P., SchulzJ.B., KuglerS. and KramerE.R., Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model, Cell Death Dis.7(9) (2016), e2359.
11.
DukeD.C., MoranL.B., PearceR.K. and GraeberM.B., The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability, Neurogenetics.8(2) (2007), 83–94. doi:10.1007/s10048-006-0077-6.
12.
DunnA.R., StoutK.A., OzawaM., LohrK.M., HoffmanC.A., BernsteinA.I.et al., Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease, Proc Natl Acad Sci USA.114(11) (2017), E2253–E2262. doi:10.1073/pnas.1616892114.
13.
DurrenbergerP.F., GrunblattE., FernandoF.S., MonoranuC.M., EvansJ., RiedererP.et al., Inflammatory pathways in Parkinson's disease; a BNE microarray study, Parkinsons Dis.2012 (2012), 214714.
14.
EganaL.A., CuevasR.A., BaustT.B., ParraL.A., LeakR.K., HochendonerS.et al., Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3, J Neurosci.29(14) (2009), 4592–4604. doi:10.1523/JNEUROSCI.4559-08.2009.
15.
FotiR., ZucchelliS., BiagioliM., RoncagliaP., VilottiS., CalligarisR.et al., Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells, J Biol Chem.285(24) (2010), 18565–18574. doi:10.1074/jbc.M109.088294.
GalterD., BuervenichS., CarmineA., AnvretM. and OlsonL., ALDH1 mRNA: Presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia, Neurobiol Dis.14(3) (2003), 637–647. doi:10.1016/j.nbd.2003.09.001.
HayashiS. and TakeichiM., Emerging roles of protocadherins: From self-avoidance to enhancement of motility, J Cell Sci.128(8) (2015), 1455–1464. doi:10.1242/jcs.166306.
20.
Heman-AckahS.M., HalleggerM., RaoM.S. and WoodM.J., RISC in PD: The impact of microRNAs in Parkinson's disease cellular and molecular pathogenesis, Front Mol Neurosci.20(6) (2013), 40.
21.
HennisM.R., MarvinM.A., TaylorC.M.2nd and GoldbergM.S., Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease, Neurobiol Dis.62 (2014), 113–123. doi:10.1016/j.nbd.2013.09.009.
22.
Hill-BurnsE.M., SinghN., GangulyP., HamzaT.H., MontimurroJ., KayD.M.et al., A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease, Pharmacogenomics J.13(6) (2013), 530–537. doi:10.1038/tpj.2012.38.
23.
HiraiH., PangZ., BaoD., MiyazakiT., LiL., MiuraE.et al., Cbln1 is essential for synaptic integrity and plasticity in the cerebellum, Nat Neurosci.8(11) (2005), 1534–1541. doi:10.1038/nn1576.
24.
IezziM., TheanderS., JanzR., LozeC. and WollheimC.B., SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment, J Cell Sci.118(Pt 23) (2005), 5647–5660.
25.
JainS., NaughtonC.K., YangM., StricklandA., VijK., EncinasM.et al., Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis, Development.131(21) (2004), 5503–5513. doi:10.1242/dev.01421.
26.
JellingerK.A., Cerebral correlates of psychotic syndromes in neurodegenerative diseases, J Cell Mol Med.16(5) (2012), 995–1012. doi:10.1111/j.1582-4934.2011.01311.x.
27.
JiaZ., GuoY., TangY., XuQ., LiB. and WuQ.Regulation of the protocadherin Celsr3 gene and its role in globus pallidus development and connectivity, Mol Cell Biol.34(20) (2014), 3895–3910. doi:10.1128/MCB.00760-14.
28.
KangA.M., PalmatierM.A. and KiddK.K., Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3), Biol Psychiatry.46(2) (1999), 151–160. doi:10.1016/S0006-3223(99)00101-8.
29.
KilpatrickI.C., JonesM.W., PycockC.J., RichesI. and PhillipsonO.T., Thalamic control of dopaminergic functions in the caudate-putamen of the rat – III. The effects of lesions in the parafascicular-intralaminar nuclei on D2 dopamine receptors and high affinity dopamine uptake, Neuroscience.19(3) (1986), 991–1005. doi:10.1016/0306-4522(86)90311-8.
30.
KleinC. and WestenbergerA., Genetics of Parkinson's disease, Cold Spring Harb Perspect Med.2(1) (2012), a008888.
31.
KleinP., Muller-RischartA.K., MotoriE., SchonbauerC., SchnorrerF., WinklhoferK.F.et al., Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants, EMBO J.33(4) (2014), 341–355. doi:10.1002/embj.201284290.
32.
KramerE.R., AronL., RamakersG.M., SeitzS., ZhuangX., BeyerK.et al., Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system, PLoS Biol.5(3) (2007), e39.
33.
KramerE.R. and LissB., GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease, FEBS Lett.589(24 Pt A) (2015), 3760–3772.
34.
LiL.F., HoP.W.L., LiuH.F., TseZ.H.M., LamC.S.C., LeungM.C.T., KungM.H.W., RamsdenD.B. and HoS.W.L., Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system [abstract], Mov Disord.31(suppl 2) (2016).
35.
LinM.K. and FarrerM.J., Genetics and genomics of Parkinson's disease, Genome Med.6(6) (2014), 48. doi:10.1186/gm566.
MandelS.A., FishmanT. and YoudimM.B., Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD, Parkinsonism Relat Disord.13(Suppl 3) (2007), S242–S247. doi:10.1016/S1353-8020(08)70009-9.
MillerR.M., CallahanL.M., CasaceliC., ChenL., KiserG.L., ChuiB.et al., Dysregulation of gene expression in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine-lesioned mouse substantia nigra, J Neurosci.24(34) (2004), 7445–7454. doi:10.1523/JNEUROSCI.4204-03.2004.
40.
MitchellR.J., HowlettS., EarlL., WhiteN.G., McCombJ., SchanfieldM.S.et al., Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations, Hum Biol.72(2) (2000), 295–304.
41.
NosratC.A., TomacA., HofferB.J. and OlsonL., Cellular and developmental patterns of expression of Ret and glial cell line-derived neurotrophic factor receptor alpha mRNAs, Exp Brain Res.115(3) (1997), 410–422. doi:10.1007/PL00005711.
42.
ParatchaG. and LeddaF., GDNF and GFRalpha: A versatile molecular complex for developing neurons, Trends Neurosci.31(8) (2008), 384–391. doi:10.1016/j.tins.2008.05.003.
43.
PiccoliG., CondliffeS.B., BauerM., GiesertF., BoldtK., De AstisS.et al., LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool, J Neurosci.31(6) (2011), 2225–2237. doi:10.1523/JNEUROSCI.3730-10.2011.
44.
RilstoneJ.J., AlkhaterR.A. and MinassianB.A., Brain dopamine-serotonin vesicular transport disease and its treatment, N Engl J Med.368(6) (2013), 543–550. doi:10.1056/NEJMoa1207281.
45.
SaalK.A., GalterD., RoeberS., BahrM., TongesL. and LingorL., Altered expression of growth associated protein-43 and Rho kinase in human patients with Parkinson's disease, Brain Pathol.27(1) (2017), 13–25. doi:10.1111/bpa.12346.
46.
SanoK., TaniharaH., HeimarkR.L., ObataS., DavidsonM., St JohnT.et al., Protocadherins: A large family of cadherin-related molecules in central nervous system, EMBO J.12(6) (1993), 2249–2256.
47.
SimunovicF., YiM., WangY., MaceyL., BrownL.T., KrichevskyA.M.et al., Gene expression profiling of substantia nigra dopamine neurons: Further insights into Parkinson's disease pathology, Brain.132(Pt 7) (2009), 1795–1809.
48.
SkeneJ.H., Axonal growth-associated proteins, Annu Rev Neurosci.12 (1989), 127–156. doi:10.1146/annurev.ne.12.030189.001015.
49.
SkeneJ.H. and WillardM., Axonally transported proteins associated with axon growth in rabbit central and peripheral nervous systems, J Cell Biol.89(1) (1981), 96–103. doi:10.1083/jcb.89.1.96.
50.
SugitaS., JanzR. and SudhofT.C., Synaptogyrins regulate Ca2+-dependent exocytosis in PC12 cells, J Biol Chem.274(27) (1999), 18893–18901. doi:10.1074/jbc.274.27.18893.
51.
SulzerD. and ZeccaL., Intraneuronal dopamine-quinone synthesis: A review, Neurotox Res.1(3) (2000), 181–195. doi:10.1007/BF03033289.
52.
UradeY., OberdickJ., Molinar-RodeR. and MorganJ.I., Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain, Proc Natl Acad Sci USA.88(3) (1991), 1069–1073. doi:10.1073/pnas.88.3.1069.
53.
WeiP., SmeyneR.J., BaoD., ParrisJ. and MorganJ.I., Mapping of Cbln1-like immunoreactivity in adult and developing mouse brain and its localization to the endolysosomal compartment of neurons, Eur J Neurosci.26(10) (2007), 2962–2978. doi:10.1111/j.1460-9568.2007.05913.x.
54.
WernerC.J., Heyny-von HaussenR., MallG. and WolfS., Proteome analysis of human substantia nigra in Parkinson's disease, Proteome Sci.6 (2008), 8. doi:10.1186/1477-5956-6-8.
55.
WesterlundM., GalterD., CarmineA. and OlsonL., Tissue- and species-specific expression patterns of class I, III, and IV Adh and Aldh 1 mRNAs in rodent embryos, Cell Tissue Res.322(2) (2005), 227–236. doi:10.1007/s00441-005-0038-7.
56.
YaoJ., NowackA., Kensel-HammesP., GardnerR.G. and BajjaliehS.M., Cotrafficking of SV2 and synaptotagmin at the synapse, J Neurosci.30(16) (2010), 5569–5578. doi:10.1523/JNEUROSCI.4781-09.2010.
57.
ZhaiD., LiS., ZhaoY. and LinZ., SLC6A3 is a risk factor for Parkinson's disease: A meta-analysis of sixteen years’ studies, Neurosci Lett.564 (2014), 99–104. doi:10.1016/j.neulet.2013.10.060.
58.
ZhengB., LiaoZ., LocascioJ.J., LesniakK.A., RoderickS.S., WattM.L.et al., PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease, Sci Transl Med.2(52) (2010), 52. doi:10.1126/scitranslmed.3001059.
